Summary

A multicenter, randomized, double-blind, placebo-controlled trial involving more than 1100 patients with major depressive disorder has affirmed the efficacy and safety of vilazodone 40 mg/day and indicated the acceptability of a dose of 20 mg/day [APA 2014 (poster NR6-103)].